Cosibelimab for advanced cutaneous squamous cell carcinoma: pharmacological rationale and clinical evidence

Rahul Ladwa, Margaret McGrath

Open source

DOI
10.1080/14712598.2026.2757937
Published
2026-11-09
Container
Expert Opinion on Biological Therapy
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14712598.2026.2757937,
  title = {Cosibelimab for advanced cutaneous squamous cell carcinoma: pharmacological rationale and clinical evidence},
  author = {Rahul Ladwa and Margaret McGrath},
  year = {2026},
  journal = {Expert Opinion on Biological Therapy},
  doi = {10.1080/14712598.2026.2757937},
  url = {https://doi.org/10.1080/14712598.2026.2757937}
}

RIS

TY  - JOUR
TI  - Cosibelimab for advanced cutaneous squamous cell carcinoma: pharmacological rationale and clinical evidence
AU  - Rahul Ladwa
AU  - Margaret McGrath
PY  - 2026
JO  - Expert Opinion on Biological Therapy
DO  - 10.1080/14712598.2026.2757937
UR  - https://doi.org/10.1080/14712598.2026.2757937
ER  - 

APA

Ladwa, R., & McGrath, M. (2026). Cosibelimab for advanced cutaneous squamous cell carcinoma: pharmacological rationale and clinical evidence. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2026.2757937

Source records